In this issue:
Neurological/neuropsychiatric complications of COVID-19
Mental health before and during the COVID-19 pandemic
Benzodiazepines: time to return to the evidence
Early-life mental health with biomarkers in midlife, and premature mortality
Intranasal olanzapine: pharmacokinetics, pharmacodynamics, safety and tolerability
Polygenic risk and progression to bipolar/psychotic disorders after early-life unipolar depression
Proteomic prediction models for transition to psychotic disorder
Low-dose testosterone for antidepressant-resistant major depressive disorder in women
Adding samidorphan to olanzapine reduces weight gain
Psilocybin-assisted therapy in major depressive disorder
Please login below to download this issue (PDF)